Min Tu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Min Tu has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Kuirong Jiang
Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
7 shared publications Dong Xu
Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210000, China; Pancreas Institute, Nanjing Medical University, Nanjing 210000, China; Jiangsu Provincial Key Laboratory of Chronic Digestive Diseases, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210000, China
3 shared publications- Jishu Wei
Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
3 shared publications Qianqian Wang
Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210000, China; Pancreas Institute, Nanjing Medical University, Nanjing 210000, China
3 shared publications- Wentao Gao
Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
3 shared publications Yang Wu
Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210000, China; Pancreas Institute, Nanjing Medical University, Nanjing 210000, China; Jiangsu Provincial Key Laboratory of Chronic Digestive Diseases, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210000, China
3 shared publications
Latest Publications
- 30 June 2026
- Published by Elsevier in Cancer Letters
- Vol. 657, 218701
Transcriptomic-based molecular classification of ampullary adenocarcinoma
- 30 June 2026
- Published by Elsevier in Cancer Letters
- Vol. 657, 218701
Transcriptomic-based molecular classification of ampullary adenocarcinoma
- Open Access
- 24 July 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1209
Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting
This study aimed to compare the benefits and identify the best second-line treatment regimen for gemcitabine-refractory unresectable pancreatic cancers. This retrospective analysis included 144 patients with unresectable pancreatic cancer who underwent a gemcitabine-based regimen as the first-line treatment. 57, 37, and 50 patients received oxaliplatin-, irinotecan-based, and modified FOLFIRINOX (mFFX) regimens, respectively. The primary endpoint of this study was progression-free survival (PFS) and the secondary endpoints were overall survival (OS), response rate, and treatment-related toxicity. There were no significant differences in median PFS (mPFS) (4.6 months vs. 2.9 months, P = 0.627, HR = 1.128, 95%CI 0.693-1.836) and median OS (mOS) (6.5 months vs. 10.2 months, P = 0.108, HR = 0.664, 95%CI 0.392-1.125) between irinotecan- and oxaliplatin-based groups. The mOS was significantly longer in the mFFX group than in the Iri/Oxa group (pooled the irinotecan- and oxaliplatin-based groups) (10.7 months vs. 8.8 months, P = 0.035, HR = 1.560, 95%CI 1.037-2.347), whereas no statistical difference was observed in mPFS between the two groups (4.4 months vs. 4.2 months, P = 0.222, HR = 1.247, 95%CI 0.866-1.797). However, after propensity score matching adjustment, no significant differences were found in mPFS (3.5 months vs. 4.2 months, P = 0.290, HR = 0.763, 95%CI 0.448-1.297) and mOS (8.5 months vs. 12.4 months, P = 0.464, HR = 1.262, 95%CI 0.673-2.367) between mFFX and Iri/Oxa groups. Survival analysis by performance status showed that patients with good performance status lived longer than those with poor performance status (10.8 months vs. 7.7 months, P = 0.000, HR = 2.194, 95%CI 1.408-3.420), suggesting that patient performance status, rather than the treatment regimen, was the primary factor affecting overall survival during second-line treatment. In the second-line treatment of pancreatic cancer, the efficacy of common treatment regimens is not significantly different, while a good performance status is the key factor influencing survival. Thus, it is recommended that supportive care be enhanced concurrently with systemic therapy in patients with pancreatic cancer.
- 24 July 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1209
Open AccessEfficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting
This study aimed to compare the benefits and identify the best second-line treatment regimen for gemcitabine-refractory unresectable pancreatic cancers. This retrospective analysis included 144 patients with unresectable pancreatic cancer who underwent a gemcitabine-based regimen as the first-line treatment. 57, 37, and 50 patients received oxaliplatin-, irinotecan-based, and modified FOLFIRINOX (mFFX) regimens, respectively. The primary endpoint of this study was progression-free survival (PFS) and the secondary endpoints were overall survival (OS), response rate, and treatment-related toxicity. There were no significant differences in median PFS (mPFS) (4.6 months vs. 2.9 months, P = 0.627, HR = 1.128, 95%CI 0.693-1.836) and median OS (mOS) (6.5 months vs. 10.2 months, P = 0.108, HR = 0.664, 95%CI 0.392-1.125) between irinotecan- and oxaliplatin-based groups. The mOS was significantly longer in the mFFX group than in the Iri/Oxa group (pooled the irinotecan- and oxaliplatin-based groups) (10.7 months vs. 8.8 months, P = 0.035, HR = 1.560, 95%CI 1.037-2.347), whereas no statistical difference was observed in mPFS between the two groups (4.4 months vs. 4.2 months, P = 0.222, HR = 1.247, 95%CI 0.866-1.797). However, after propensity score matching adjustment, no significant differences were found in mPFS (3.5 months vs. 4.2 months, P = 0.290, HR = 0.763, 95%CI 0.448-1.297) and mOS (8.5 months vs. 12.4 months, P = 0.464, HR = 1.262, 95%CI 0.673-2.367) between mFFX and Iri/Oxa groups. Survival analysis by performance status showed that patients with good performance status lived longer than those with poor performance status (10.8 months vs. 7.7 months, P = 0.000, HR = 2.194, 95%CI 1.408-3.420), suggesting that patient performance status, rather than the treatment regimen, was the primary factor affecting overall survival during second-line treatment. In the second-line treatment of pancreatic cancer, the efficacy of common treatment regimens is not significantly different, while a good performance status is the key factor influencing survival. Thus, it is recommended that supportive care be enhanced concurrently with systemic therapy in patients with pancreatic cancer.
- Open Access
- 20 May 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 901
The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal drainage post-surgery: a retrospective cohort study
Objective: Pancreatectomy remains associated with a high incidence of complications. In certain cases, patients with pancreatic ductal adenocarcinoma (PDAC) face challenges in removing intraperitoneal drainage after surgery, leading to potential delays in the administration of adjuvant chemotherapy (AC) and potentially impacting survival outcomes. The objective of this study was to evaluate the feasibility and potential benefits of AC in PDAC patients who are unable to remove intraperitoneal drainage over 30 days. Methods: Between January 2021 and December 2022, a total of 220 patients with resected PDAC received AC at our center. Among them, 84 patients experienced persistent intraperitoneal drainage lasting more than 30 days postoperatively. Of these, 38 patients (45.2%) initiated AC despite the ongoing presence of drainage and were classified as the AC(d+) group, while the remaining 46 patients (54.8%) began AC only after successful drainage removal, and were categorized as the AC(d−) group. The other 136 patients, who underwent prompt removal of intraperitoneal drainage, were assigned to the AC(pr) group. Baseline information, surgery-related outcomes, and chemotherapy-related adverse events were collected and compared between the two groups, and factors that affected recurrence-free survival (RFS) were also analysed. Results: Of the 220 patients included in the study, 107 (48.7%) experienced grade 3–4 chemotherapy-related adverse events. The interval from surgery to the initiation of AC was similar between the AC(d+) and AC(pr) groups (50 vs. 57 days, P = 0.108). However, it was significantly shorter in the AC(d+) group compared to the AC(d−) group (50 vs. 61 days, P = 0.015). Notably, no additional chemotherapy-related adverse events were observed in the AC(d+) group compared to either the AC(d−) or AC(pr) groups. The estimated 1-year and 2-year survival rates were 85.6% and 60.5%, respectively, for the AC(d−) group, and 95.8% and 61.0% for the AC(d+) group. In the AC(pr) group, the corresponding survival rates were 89.1% and 64.0%. Cox multivariate regression analysis demonstrated that tumour grade differentiation, completed six cycles of therapy, the interval from surgery to the initiation of AC and resection margins were independent factors affecting RFS. Conclusion: Administering AC was safe for patients who underwent resection for PDAC and encountered challenges in the prompt removal of intraperitoneal drainage beyond 30 days post-surgery. The proactive management of preventing delays in chemotherapy administration could reduce the early recurrence risk in this particular patient cohort.
- 20 May 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 901
Open AccessThe feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal drainage post-surgery: a retrospective cohort study
Objective: Pancreatectomy remains associated with a high incidence of complications. In certain cases, patients with pancreatic ductal adenocarcinoma (PDAC) face challenges in removing intraperitoneal drainage after surgery, leading to potential delays in the administration of adjuvant chemotherapy (AC) and potentially impacting survival outcomes. The objective of this study was to evaluate the feasibility and potential benefits of AC in PDAC patients who are unable to remove intraperitoneal drainage over 30 days. Methods: Between January 2021 and December 2022, a total of 220 patients with resected PDAC received AC at our center. Among them, 84 patients experienced persistent intraperitoneal drainage lasting more than 30 days postoperatively. Of these, 38 patients (45.2%) initiated AC despite the ongoing presence of drainage and were classified as the AC(d+) group, while the remaining 46 patients (54.8%) began AC only after successful drainage removal, and were categorized as the AC(d−) group. The other 136 patients, who underwent prompt removal of intraperitoneal drainage, were assigned to the AC(pr) group. Baseline information, surgery-related outcomes, and chemotherapy-related adverse events were collected and compared between the two groups, and factors that affected recurrence-free survival (RFS) were also analysed. Results: Of the 220 patients included in the study, 107 (48.7%) experienced grade 3–4 chemotherapy-related adverse events. The interval from surgery to the initiation of AC was similar between the AC(d+) and AC(pr) groups (50 vs. 57 days, P = 0.108). However, it was significantly shorter in the AC(d+) group compared to the AC(d−) group (50 vs. 61 days, P = 0.015). Notably, no additional chemotherapy-related adverse events were observed in the AC(d+) group compared to either the AC(d−) or AC(pr) groups. The estimated 1-year and 2-year survival rates were 85.6% and 60.5%, respectively, for the AC(d−) group, and 95.8% and 61.0% for the AC(d+) group. In the AC(pr) group, the corresponding survival rates were 89.1% and 64.0%. Cox multivariate regression analysis demonstrated that tumour grade differentiation, completed six cycles of therapy, the interval from surgery to the initiation of AC and resection margins were independent factors affecting RFS. Conclusion: Administering AC was safe for patients who underwent resection for PDAC and encountered challenges in the prompt removal of intraperitoneal drainage beyond 30 days post-surgery. The proactive management of preventing delays in chemotherapy administration could reduce the early recurrence risk in this particular patient cohort.
- Open Access
- 20 April 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. Publish Ah (7) , 2096-2119
Risk factors of delayed gastric emptying in patients after pancreaticoduodenectomy: a comprehensive systematic review and meta-analysis
Background: Delayed gastric emptying (DGE) is a common complication after pancreaticoduodenectomy (PD) or pylorus preserving pancreaticoduodenectomy (PPPD). However, its risk factors are still unclear. This meta-analysis aimed to identify the potential risk factors of DGE among patients undergoing PD or PPPD. Methods: We searched PubMed, EMBASE, Web of Science, Cochrane Library, Google Scholar and ClinicalTrial.gov for studies that examined the clinical risk factors of DGE after PD or PPPD from inception through July 31, 2022. We pooled odds ratios (ORs) with 95% confidence intervals (CIs) using random-effects or fixed-effects models. We also performed heterogeneity, sensitivity, and publication bias analyses. Results: The study included a total of 31 research studies, which involved 9205 patients. The pooled analysis indicated that out of 16 non-surgical related risk factors, three risk factors were found to be associated with an increased incidence of DGE. These risk factors were older age (OR 1.37, P=0.005), pre-operative biliary drainage (OR 1.34, P=0.006), and soft pancreas texture (OR 1.23, P=0.04). On the other hand, patients with dilated pancreatic duct (OR 0.59, P=0.005) had a decreased risk of DGE. Among 12 operation related risk factors,more blood loss (OR 1.33, P=0.01), post-operative pancreatic fistula (POPF) (OR 2.09, PP=0.001), and intra-abdominal abscess (OR 3.06, P<0.0001) were more likely to cause DGE. However, our data also revealed 20 factors did not support stimulative factors influencing DGE. Conclusion: Age, pre-operative biliary drainage, pancreas texture, pancreatic duct size, blood loss, POPF, intra-abdominal collection and intra-abdominal abscess are significantly associated with DGE. This meta-analysis may have utility in guiding clinical practice for improvements for screening patients with high risk of DGE and selecting appropriate treatment measure.
- 20 April 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. Publish Ah (7) , 2096-2119
Open AccessRisk factors of delayed gastric emptying in patients after pancreaticoduodenectomy: a comprehensive systematic review and meta-analysis
Background: Delayed gastric emptying (DGE) is a common complication after pancreaticoduodenectomy (PD) or pylorus preserving pancreaticoduodenectomy (PPPD). However, its risk factors are still unclear. This meta-analysis aimed to identify the potential risk factors of DGE among patients undergoing PD or PPPD. Methods: We searched PubMed, EMBASE, Web of Science, Cochrane Library, Google Scholar and ClinicalTrial.gov for studies that examined the clinical risk factors of DGE after PD or PPPD from inception through July 31, 2022. We pooled odds ratios (ORs) with 95% confidence intervals (CIs) using random-effects or fixed-effects models. We also performed heterogeneity, sensitivity, and publication bias analyses. Results: The study included a total of 31 research studies, which involved 9205 patients. The pooled analysis indicated that out of 16 non-surgical related risk factors, three risk factors were found to be associated with an increased incidence of DGE. These risk factors were older age (OR 1.37, P=0.005), pre-operative biliary drainage (OR 1.34, P=0.006), and soft pancreas texture (OR 1.23, P=0.04). On the other hand, patients with dilated pancreatic duct (OR 0.59, P=0.005) had a decreased risk of DGE. Among 12 operation related risk factors,more blood loss (OR 1.33, P=0.01), post-operative pancreatic fistula (POPF) (OR 2.09, PP=0.001), and intra-abdominal abscess (OR 3.06, P<0.0001) were more likely to cause DGE. However, our data also revealed 20 factors did not support stimulative factors influencing DGE. Conclusion: Age, pre-operative biliary drainage, pancreas texture, pancreatic duct size, blood loss, POPF, intra-abdominal collection and intra-abdominal abscess are significantly associated with DGE. This meta-analysis may have utility in guiding clinical practice for improvements for screening patients with high risk of DGE and selecting appropriate treatment measure.
- Open Access
- 1 June 2022
- Published by Springer Nature in Molecular Cancer
- Vol. 21 (1) , 1-23
CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2
Background: circular RNAs (circRNAs) have been reported to play crucial roles in the biology of different cancers. However, little is known about the function of circSTX6 (hsa_circ_0007905) in pancreatic ductal adenocarcinoma (PDAC). Methods: circSTX6, a circRNA containing exons 4, 5, 6 and 7 of the STX6 gene, was identified by RNA sequencing and detected by quantitative reverse transcription PCR (qRT–PCR). The biological function of circSTX6 was assessed in vitro and in vivo. The relationship between circSTX6 and miR-449b-5p was confirmed by biotin-coupled circRNA capture, fluorescence in situ hybridization (FISH) and luciferase reporter assays. The interaction of circSTX6 with Cullin 2 (CUL2) was verified by RNA–protein RNA pull-down, RNA immunoprecipitation (RIP) and western blotting assays. Results: circSTX6 was frequently upregulated in PDAC tissues, and circSTX6 overexpression promoted tumor proliferation and metastasis both in vitro and in vivo. Furthermore, circSTX6 expression was associated with tumor differentiation and N stage. Mechanistically, circSTX6 regulated the expression of non-muscle myosin heavy chain 9 (MYH9) by sponging miR-449b-5p. Moreover, circSTX6 was confirmed to participate in the ubiquitin-dependent degradation of hypoxia-inducible factor 1-alpha (HIF1A) by interacting with CUL2 and subsequently accelerating the transcription of MYH9. Conclusions: Our findings indicate that circSTX6 facilitates proliferation and metastasis of PDAC cells by regulating the expression of MYH9 through the circSTX6/miR-449b-5p axis and circSTX6/CUL2/HIF1A signaling pathway. Therefore, circSTX6 could serve as a potential therapeutic target for the treatment of PDAC.
- 1 June 2022
- Published by Springer Nature in Molecular Cancer
- Vol. 21 (1) , 1-23
Open AccessCircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2
Background: circular RNAs (circRNAs) have been reported to play crucial roles in the biology of different cancers. However, little is known about the function of circSTX6 (hsa_circ_0007905) in pancreatic ductal adenocarcinoma (PDAC). Methods: circSTX6, a circRNA containing exons 4, 5, 6 and 7 of the STX6 gene, was identified by RNA sequencing and detected by quantitative reverse transcription PCR (qRT–PCR). The biological function of circSTX6 was assessed in vitro and in vivo. The relationship between circSTX6 and miR-449b-5p was confirmed by biotin-coupled circRNA capture, fluorescence in situ hybridization (FISH) and luciferase reporter assays. The interaction of circSTX6 with Cullin 2 (CUL2) was verified by RNA–protein RNA pull-down, RNA immunoprecipitation (RIP) and western blotting assays. Results: circSTX6 was frequently upregulated in PDAC tissues, and circSTX6 overexpression promoted tumor proliferation and metastasis both in vitro and in vivo. Furthermore, circSTX6 expression was associated with tumor differentiation and N stage. Mechanistically, circSTX6 regulated the expression of non-muscle myosin heavy chain 9 (MYH9) by sponging miR-449b-5p. Moreover, circSTX6 was confirmed to participate in the ubiquitin-dependent degradation of hypoxia-inducible factor 1-alpha (HIF1A) by interacting with CUL2 and subsequently accelerating the transcription of MYH9. Conclusions: Our findings indicate that circSTX6 facilitates proliferation and metastasis of PDAC cells by regulating the expression of MYH9 through the circSTX6/miR-449b-5p axis and circSTX6/CUL2/HIF1A signaling pathway. Therefore, circSTX6 could serve as a potential therapeutic target for the treatment of PDAC.
- 1 February 2022
- Published by Wolters Kluwer Health in Zhonghua Wai Ke Za Zhi [chinese Journal of Surgery]
- Vol. 60 (2) , 128-133
[Comparative clinical efficacy analysis of pancreatoduodenectomy for distal bile duct and pancreatic head cancer: a report of 1 005 cases].
Objective: To compare and analyze the clinical efficacy of pancreaticoduodenectomy for distal bile duct cancer and pancreatic head cancer. Methods: Clinical data of 1 005 patients who underwent pancreaticoduodenectomy and postoperative pathological examination confirmed the diagnosis of distal bile duct cancer and pancreatic head cancer at the Pancreas Center of the First Affiliated Hospital of Nanjing Medical University from January 2016 to December 2020 were analyzed retrospectively. There were 112 cases in the distal bile duct cancer group, 71 males and 41 females,with age (M(IQR)) of 65(15) years(range: 40 to 87 years); 893 cases in the pancreatic head cancer group, 534 males and 359 females,with age of 64(13)years(range: 16 to 91 years). The differences between clinicopathological characteristics and postoperative overall survival of the two groups were analyzed by χ2 test, Fisher's exact probability method, rank sum test or log-rank test, respectively. The difference in postoperative overall survival between the two groups was compared using Kaplan-Meier method after propensity score matching (1∶1). Results: Compared with the pancreatic head cancer group,the distal bile duct cancer group had shorter operative time (240.0(134.0) minutes vs. 261.0(97.0) minutes, Z=2.712, P=0.007),less proportion of combined venous resection (4.5% (5/112) vs. 19.4% (173/893), χ²=15.177,Pvs. 3.0(1.5) cm,Z=10.567,Pvs. 38.0% (337/893), χ²=7.328, P=0.007),fewer positive lymph nodes (0(1) vs. 1(3), Z=5.824, Pvs. 38.3%(342/893), χ²=64.399, Pvs. 36.3% (324/892), χ²=7.913,P=0.005),postoperative pancreatic fistula (28.6% (32/112) vs. 13.9% (124/893), χ²=16.318,Pvs. 8.6% (77/892), χ²=18.001,Pvs. 35.1 months,Z=1.640,P=0.201),and multifactorial analysis showed that tumor site was not an independent risk factor affecting the prognosis of patients in both groups after matching (HR=0.73,95%CI:0.43 to 1.23,P=0.238). Conclusions: Patients with distal bile duct cancer are more likely to benefit from early diagnosis and surgical treatment than patients with pancreatic head cancer,but with a relative higher postoperative complication rates. The different tumor origin site is not an independent risk factor for prognosis of patients with distal bile duct cancer and pancreatic head cancer after propensity score matching.
- 1 February 2022
- Published by Wolters Kluwer Health in Zhonghua Wai Ke Za Zhi [chinese Journal of Surgery]
- Vol. 60 (2) , 128-133
[Comparative clinical efficacy analysis of pancreatoduodenectomy for distal bile duct and pancreatic head cancer: a report of 1 005 cases].
Objective: To compare and analyze the clinical efficacy of pancreaticoduodenectomy for distal bile duct cancer and pancreatic head cancer. Methods: Clinical data of 1 005 patients who underwent pancreaticoduodenectomy and postoperative pathological examination confirmed the diagnosis of distal bile duct cancer and pancreatic head cancer at the Pancreas Center of the First Affiliated Hospital of Nanjing Medical University from January 2016 to December 2020 were analyzed retrospectively. There were 112 cases in the distal bile duct cancer group, 71 males and 41 females,with age (M(IQR)) of 65(15) years(range: 40 to 87 years); 893 cases in the pancreatic head cancer group, 534 males and 359 females,with age of 64(13)years(range: 16 to 91 years). The differences between clinicopathological characteristics and postoperative overall survival of the two groups were analyzed by χ2 test, Fisher's exact probability method, rank sum test or log-rank test, respectively. The difference in postoperative overall survival between the two groups was compared using Kaplan-Meier method after propensity score matching (1∶1). Results: Compared with the pancreatic head cancer group,the distal bile duct cancer group had shorter operative time (240.0(134.0) minutes vs. 261.0(97.0) minutes, Z=2.712, P=0.007),less proportion of combined venous resection (4.5% (5/112) vs. 19.4% (173/893), χ²=15.177,Pvs. 3.0(1.5) cm,Z=10.567,Pvs. 38.0% (337/893), χ²=7.328, P=0.007),fewer positive lymph nodes (0(1) vs. 1(3), Z=5.824, Pvs. 38.3%(342/893), χ²=64.399, Pvs. 36.3% (324/892), χ²=7.913,P=0.005),postoperative pancreatic fistula (28.6% (32/112) vs. 13.9% (124/893), χ²=16.318,Pvs. 8.6% (77/892), χ²=18.001,Pvs. 35.1 months,Z=1.640,P=0.201),and multifactorial analysis showed that tumor site was not an independent risk factor affecting the prognosis of patients in both groups after matching (HR=0.73,95%CI:0.43 to 1.23,P=0.238). Conclusions: Patients with distal bile duct cancer are more likely to benefit from early diagnosis and surgical treatment than patients with pancreatic head cancer,but with a relative higher postoperative complication rates. The different tumor origin site is not an independent risk factor for prognosis of patients with distal bile duct cancer and pancreatic head cancer after propensity score matching.
- Open Access
Identification of FEZ2 as a potential oncogene in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the common malignant tumors with high lethal rate and poor prognosis. Dysregulation of many genes have been reported to be involved in the occurrence and development of PDAC. However, as a highly conserved gene in eukaryotes, the role of Fasciculation and Elongation protein Zeta 2 (FEZ2) in pancreatic cancer progression is not clear. In this study, we identified the oncogenic effect of FEZ2 on PDAC. By mining of The Cancer Genome Atlas (TCGA) database, we found that FEZ2 was upregulated in PDAC tissues and FEZ2 expression was negatively regulated by its methylation. Moreover, high expression and low methylation of FEZ2 correlated with poor prognosis in PDAC patients. Besides, we found that FEZ2 could promote PDAC cells proliferation, migration and 5-FU resistance in vitro. Furthermore, Gene pathway enrichment analysis demonstrated a positive correlation between Wnt signaling activation and FEZ2 expression in PDAC patients. Western blot showed that FEZ2 knockdown significantly suppressed β-catenin expression. Collectively, our finding revealed that FEZ2 functioned as a potential oncogene on PDAC progression and migration, and the expression of FEZ2 had guidance value for the treatment and chemotherapy program of PDAC patients.
Open AccessIdentification of FEZ2 as a potential oncogene in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the common malignant tumors with high lethal rate and poor prognosis. Dysregulation of many genes have been reported to be involved in the occurrence and development of PDAC. However, as a highly conserved gene in eukaryotes, the role of Fasciculation and Elongation protein Zeta 2 (FEZ2) in pancreatic cancer progression is not clear. In this study, we identified the oncogenic effect of FEZ2 on PDAC. By mining of The Cancer Genome Atlas (TCGA) database, we found that FEZ2 was upregulated in PDAC tissues and FEZ2 expression was negatively regulated by its methylation. Moreover, high expression and low methylation of FEZ2 correlated with poor prognosis in PDAC patients. Besides, we found that FEZ2 could promote PDAC cells proliferation, migration and 5-FU resistance in vitro. Furthermore, Gene pathway enrichment analysis demonstrated a positive correlation between Wnt signaling activation and FEZ2 expression in PDAC patients. Western blot showed that FEZ2 knockdown significantly suppressed β-catenin expression. Collectively, our finding revealed that FEZ2 functioned as a potential oncogene on PDAC progression and migration, and the expression of FEZ2 had guidance value for the treatment and chemotherapy program of PDAC patients.
- 1 December 2020
- Published by Elsevier in Cancer Letters
- Vol. 494, 107-120
Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK signaling pathway
- 1 December 2020
- Published by Elsevier in Cancer Letters
- Vol. 494, 107-120
Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK signaling pathway
- Open Access
- 21 March 2017
- Published by Springer Nature in Molecular Cancer
- Vol. 16 (1) , 1-12
Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
Vasohibin 2 (VASH2) has previously been identified as an agiogenenic factor and a cancer related protein. Here we investigated the association of VASH2 expression and chemoresistance in pancreatic cancer. Immunohistochemical staining for VASH2 was performed on 102 human pancreatic cancer samples. Pancreatic cancer cell line models exhibiting overexpression or knockdown of VASH2 were generated. Gene expression analyses were carried out to determine genes differentially regulated by VASH2. Putative transcription factors that are downstream mediators of gene expression regulated by VASH2 were queried bioinformatically. Dual-luciferase reporter assays and ChIP assays were performed to confirm transactivation of target genes following VASH2 overexpression or knockdown. VASH2 protein expression was higher in human pancreatic cancer than in paired adjacent tissues and elevated VASH2 levels were associated with gemcitabine chemoresistance. In cell line models of pancreatic cancer, VASH2 expression induced gemcitabine chemoresistance in vitro and in vivo. It was discovered that expression of ribonucleotide reductase regulatory subunit M2 (RRM2) is regulated by VASH2; immunohistochemical analysis demonstrated a positive association of VASH2 expression and RRM2 expression in human pancreatic cancer tissues. Bioinformatics analyses revealed that induction of the Jun proto-oncogene (JUN) by VASH2 is responsible for upregulation of RRM2 expression; this JUN-dependent regulation of RRM2 by VASH2 was confirmed by chromatin immunoprecipitation and dual luciferase reporter assays, which demonstrated that JUN directly binds with the RRM2 promoter to activate transcription. These data suggest that VASH2 reduces the chemosensitivity to gemcitabine in pancreatic cancer cells via JUN-dependent transactivation of RRM2.
- 21 March 2017
- Published by Springer Nature in Molecular Cancer
- Vol. 16 (1) , 1-12
Open AccessVasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
Vasohibin 2 (VASH2) has previously been identified as an agiogenenic factor and a cancer related protein. Here we investigated the association of VASH2 expression and chemoresistance in pancreatic cancer. Immunohistochemical staining for VASH2 was performed on 102 human pancreatic cancer samples. Pancreatic cancer cell line models exhibiting overexpression or knockdown of VASH2 were generated. Gene expression analyses were carried out to determine genes differentially regulated by VASH2. Putative transcription factors that are downstream mediators of gene expression regulated by VASH2 were queried bioinformatically. Dual-luciferase reporter assays and ChIP assays were performed to confirm transactivation of target genes following VASH2 overexpression or knockdown. VASH2 protein expression was higher in human pancreatic cancer than in paired adjacent tissues and elevated VASH2 levels were associated with gemcitabine chemoresistance. In cell line models of pancreatic cancer, VASH2 expression induced gemcitabine chemoresistance in vitro and in vivo. It was discovered that expression of ribonucleotide reductase regulatory subunit M2 (RRM2) is regulated by VASH2; immunohistochemical analysis demonstrated a positive association of VASH2 expression and RRM2 expression in human pancreatic cancer tissues. Bioinformatics analyses revealed that induction of the Jun proto-oncogene (JUN) by VASH2 is responsible for upregulation of RRM2 expression; this JUN-dependent regulation of RRM2 by VASH2 was confirmed by chromatin immunoprecipitation and dual luciferase reporter assays, which demonstrated that JUN directly binds with the RRM2 promoter to activate transcription. These data suggest that VASH2 reduces the chemosensitivity to gemcitabine in pancreatic cancer cells via JUN-dependent transactivation of RRM2.
- Open Access
- 5 March 2012
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 12 (1) , 475-481
Overexpression of serine/threonine-protein kinase-1 in pancreatic cancer tissue: Serine/threonine-protein kinase-1 knockdown increases the chemosensitivity of pancreatic cancer cells
Serine/threonine-protein kinase-1 (SMG-1) belongs to the phosphatidylinositol 3‑kinase‑related kinase family. Altered expression of SMG-1 contributes to human carcinogenesis and cancer progression. The present study detected the expression levels of SMG-1 in normal and cancerous pancreatic tissues and then assessed the effects of SMG-1-knockdown in pancreatic cancer cell lines in vitro. A pancreatic cancer tissue array and pancreatic cancer cell lines were used to detect the expression levels of SMG-1 and a lentivirus expressing either SMG-1 or negative control short hairpin (sh)RNA were used to knock down the expression of SMG-1 in the pancreatic cancer cell lines. Western blot, cell proliferation, Cell Counting kit-8, Transwell tumor cell migration and invasion assays, and flow cytometric analysis of cell apoptosis with or without gemcitabine or cisplatin treatment were performed to assess the tumor cells. The protein expression of SMG-1 was higher in the pancreatic cancer tissues and cells compared with the normal tissues. sh-SMG-1 lentivirus infection significantly suppressed the expression of SMG-1 in the pancreatic cancer cell lines, resulting in the inhibition of tumor cell proliferation and increased chemosensitivity to treatment with gemcitabine and cisplatin. However, SMG-1 knockdown had no effect on pancreatic cancer cell migration or invasion capacities. The protein expression of SMG-1 was increased in the pancreatic cancer tissues and was associated with an advanced tumor stage. Knock down of the expression of SMG-1 inhibited tumor cell proliferation and induced the chemosensitivity of pancreatic cancer cells in vitro.
- 5 March 2012
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 12 (1) , 475-481
Open AccessOverexpression of serine/threonine-protein kinase-1 in pancreatic cancer tissue: Serine/threonine-protein kinase-1 knockdown increases the chemosensitivity of pancreatic cancer cells
Serine/threonine-protein kinase-1 (SMG-1) belongs to the phosphatidylinositol 3‑kinase‑related kinase family. Altered expression of SMG-1 contributes to human carcinogenesis and cancer progression. The present study detected the expression levels of SMG-1 in normal and cancerous pancreatic tissues and then assessed the effects of SMG-1-knockdown in pancreatic cancer cell lines in vitro. A pancreatic cancer tissue array and pancreatic cancer cell lines were used to detect the expression levels of SMG-1 and a lentivirus expressing either SMG-1 or negative control short hairpin (sh)RNA were used to knock down the expression of SMG-1 in the pancreatic cancer cell lines. Western blot, cell proliferation, Cell Counting kit-8, Transwell tumor cell migration and invasion assays, and flow cytometric analysis of cell apoptosis with or without gemcitabine or cisplatin treatment were performed to assess the tumor cells. The protein expression of SMG-1 was higher in the pancreatic cancer tissues and cells compared with the normal tissues. sh-SMG-1 lentivirus infection significantly suppressed the expression of SMG-1 in the pancreatic cancer cell lines, resulting in the inhibition of tumor cell proliferation and increased chemosensitivity to treatment with gemcitabine and cisplatin. However, SMG-1 knockdown had no effect on pancreatic cancer cell migration or invasion capacities. The protein expression of SMG-1 was increased in the pancreatic cancer tissues and was associated with an advanced tumor stage. Knock down of the expression of SMG-1 inhibited tumor cell proliferation and induced the chemosensitivity of pancreatic cancer cells in vitro.